孔雅娴研究员，教授，首都医科大学博士研究生导师，兼任北京大学医学部免疫学博士研究生导师。北京市杰青科学基金获得者，传染病溯源预警与智能决策全国重点实验室PI。课题组目前有助理研究员1人，研究实习员1人，博士研究生4人，硕士研究生4人。

        课题组主要致力于感染性疾病的免疫耗竭与衰老调控机制研究，主要研究方向包括：多种免疫细胞互作机制、免疫细胞新亚群新功能的发现、免疫细胞代谢重塑机制等。课题组研究方向清晰明确，科研经费充足，学术气氛浓厚，学术产出稳步提升，拥有严谨活泼、团结互助的课题组文化。

在研项目：

1. 北京市自然科学基金-昌平创新联合基金培育项目，国产九价人乳头瘤病毒疫苗在不同免疫重建程度HIV感染男性中的安全性与持久免疫原性的研究，2025.07-2028-06，30万元，在研，主持

 2. 国家区域医疗中心临床研究项目，早期口服阿司匹林改善HIV-1感染者免疫重建的临床研究，2025.07-2027-06，60万元，在研，主持

 3. 国家自然科学基金面上项目，82471585，CD226通过戊二酸-HIF-2α轴调控铁死亡途径促进T细胞衰老的分子机制研究，2025.01 - 2028.12， 49万元，在研，主持

 4. 北京市医院管理中心“登峰”人才计划，DFL20241802，2024/01-2027/12，160万元，在研，主持

5. 北京市卫健委高层次公共卫生技术人才学科骨干，02-027，2023/01-2025/12，42万元，在研，主持

中国人体健康科技促进会免疫缺陷监测与转化专委会常委

中国防痨协会人兽共患结核病专委会常委

北京慢性病防治与健康教育研究会感染性疾病专业委员会常委

中国性病艾滋病防治协会学术委员会青年委员

中国研究型医院学会肝病专委会青年委员

Infectious Disease & Immunity 青年编委

1.     Wu Y,Liu X, Yu L, Yan H, Xie Y, Pu Q, Liang Y, Kong Y(孔雅娴)*, YangZ*. Value of CD8+ T cell-related genes and IL-6/STAT3 signaling pathway in theprognosis of HCC and experimental investigation. Int J Biol Macromol.2025 Oct 30;332(Pt 2):148526.

2.     Wu Y,Liu X, Xie Y, Yu L, Yan H, Pu Q, Cai X, Liang Y, Kong Y(孔雅娴)*, YangZ*. Mechanism of Jiedu Prescription in Hepatocellular Carcinoma: IntegratingNetwork Pharmacology and Experimental Validation. Integr Cancer Ther.2025 Jan-Dec;24:15347354251380219. doi: 10.1177/15347354251380219.

3.     Zhang R#,Mu Y#, Zhang M#, Wu H, Xu Y, Zhao C, Liu Z, Lin L, Zhang W, Kong Y(孔雅娴)#, ChenZ*. Lactate Dehydrogenase/Albumin to Urea Ratio: A Novel Prognostic Indicatorfor Adverse Outcomes in Patients With Severe Fever With ThrombocytopeniaSyndrome. J Med Virol. 2025 Jun;97(6):e70428.

4.     ZhangL#, Zhao H#, Chen N#, Wang X#, Du J, Wang D, Liu Y, Wei Y, Zhang M, Deng M,Jiang M, Kong Y(孔雅娴)*.Increased frequency of Foxp3+CD8+T cells is associated with disease progressionduring HIV infection. AIDS. 2025 Jul 1;39(8):946-956.

5.     ChenN#, Zhang L#, Wang X#, He Z, Wang D, Du J, Deng M, Zhang M, Jiang M, Wei Y,Zhao M, Liu Y, Wang X, Zhao H*, KongY(孔雅娴)*. Increased levels of Foxp3+CD4+NKT-likecells are associated with HIV disease progression. Clin Immunol.2025 May 27;278:110533.

6.    Wang X, Kong Y(孔雅娴)*. Advancing mechanistic understanding ofpost-acute sequelae of Ebola virus disease. Lancet Microbe. 2025 Apr18:101139. doi: 10.1016/j.lanmic.

7.    Wang X, Kong Y(孔雅娴)*. Crucialanalysis of Nef-mediated MHC-I modulation in the maintenance of the HIV-1reservoir. Lancet Microbe. 2025 Apr1:101133. doi: 10.1016/j.lanmic.2025.101133.

8.     Xie Y, Yan F, Liu X, Yu L, Yan H, Shang Z, Kong Y(孔雅娴)*, Yang Z*. FoxO1 as a Hub in Immunosenescence Inducedby Hepatocellular Carcinoma and the Effect of Yangyin Fuzheng JieduPrescription. Drug Des Devel Ther. 2025Mar 5;19:1543-1560.

9.     Xie Y,Yan F, Yu L, Yan H, Kong Y(孔雅娴)*, Yang Z*. Mechanism of Shashen-Maidongherb pair in treating hepatocellular carcinoma using network pharmacology andexperimental validation. J Ethnopharmacol. 2025 Jan 30;337(Pt3):118954. doi: 10.1016/j.jep.2024.118954.

10. Wang X, Wei Y, He Z, Wang D, Zhang L, DuJ, Zhang M, Jiang M, Chen N, Deng M, Li B, Song C, Chen D, Liu H, Xiao J, LiangH, Zhao H, Kong Y(孔雅娴)*.CD70-inducedDifferentiation of Proinflammatory Th1/17/22/GM Lymphocytes Associated withDisease Progression and Immune Reconstitution During HIV Infection. EmergingMicrobes & Infections. 2023 Dec;12(2):2271068

11. Wu Y, Liu X, Wang X, Yu L, Yan H, Xie Y,Pu Q, Cai X, Kong Y(孔雅娴)*, Yang Z*. A Nomogram Prognostic Model forAdvanced Hepatocellular Carcinoma Based on the Interaction Between CD8+T CellCounts and Age. Onco Targets Ther. 2023 Sep 21;16:753-766.

12. Zhang L, Wei Y, Wang D, Du J, Wang X, LiB, Jiang M, Zhang M, Chen N, Deng M, Song C, Chen D, Wu L, Xiao J, Liang H,Zhao H, Kong Y(孔雅娴)*. Elevated Foxp3+ double-negative T cellsare associated with disease progression during HIV infection. Front.Immunol. 13:947647. doi: 10.3389/fimmu.2022.947647

13. Wang X, Zhang L, Du J, Wei Y, Wang D, SongC, Chen D, Li B, Jiang M, Zhang M, Zhao H , Kong Y(孔雅娴)*. Decreased CD73+ Double-Negative T Cellsand Elevated Level of Soluble CD73 Correlated With and Predicted Poor ImmuneReconstitution in HIV-Infected Patients After Antiretroviral Therapy. Front. Immunol. 13:869286.

14. Wang X#, Wang D#, Du J#, Wei Y, Song R,Wang B, Qiu S, Li B, Zhang L, Zeng Y, Zhao H, Kong Y(孔雅娴)*. High Levels of CD244 Rather Than CD160Associate With CD8+ T-Cell Aging. Front Immunol. 2022 Mar21;13:853522.

15.  Li Y#, KongY (孔雅娴)#, ShiK, Huang Y, Zhang Q, Zhu B, Zeng H*, Wang X*. CD200R CombinedNeutrophil-Lymphocyte Ratio Predict 90-Day Mortality in HBV-RelatedAcute-On-Chronic Liver Failure. FrontMed (Lausanne). 2021Dec 6;8:762296. (IF:5.091)

16.  Wang D,Jiang Y, Song Y, Zeng Y, Li C, Wang X, Liu Y, Xiao J, Kong Y(孔雅娴)*,Zhao H*. Altered T-Cell Subsets are Associated with Dysregulated CytokineSecretion of CD4+ T Cells During HIV Infection. JInflamm Res. 2021 Oct7;14:5149-5163.

17.  Du J#,Wei L#, Li G#, Hua M#, Sun Y, Wang D, Han K, Yan Y, Song C, Song R, Zhang H,Han J*, Liu J*, Kong Y(孔雅娴)*.Persistent High Percentage of HLA-DR+CD38high CD8+ T Cells Associated WithImmune Disorder and Disease Severity of COVID-19. Front.Immunol., 2021 Sep9;12:735125. doi: 10.3389/fimmu.2021.735125.

18.  Kong Y (孔雅娴)#,Wang Y#, Wu X#, Han J, Li G, Hua M, Han K, Zhang H*, Li A*, Zeng H*. Storm ofsoluble immune checkpoints associated with disease severity of COVID-19. SignalTransduct Target Ther. 2020Sep 7;5(1):192. doi: 10.1038/s41392-020-00308-2.

19.  Kong Y (孔雅娴)#*,Han J#, Wu X#, Zeng H, Liu J*, Zhang H*. VEGF-D: a novel biomarker fordetection of COVID-19 progression. Version 2. CritCare. 2020 Jun 23;24(1):373. doi:10.1186/s13054-020-03079-y.

20.  Du J,Li G, Hua M, Han J, Hao Y, Zeng H, Li A, Kong Y (孔雅娴)*.PDK1/mTOR Signaling in Myeloid Cells Differentially Regulates the Early andLate Stages of Sepsis. Mediators Inflamm. 2020Jul 25;2020:5437175.

21. Wang D, Du J, Song Y, Wang B, Song R, HaoY, Zeng Y, Xiao J, Zheng H, Zeng H, Zhao H*, Kong Y (孔雅娴)*.CD70 contributes to age-associated T cell defects and overwhelming inflammatoryresponses. Aging(Albany NY). 2020Jun 19;12(12):12032-12050.

22. Liu X, Li M, Wang X, Dang Z, Jiang Y, WangX, Kong Y (孔雅娴)*, Yang Z*. PD-1+ TIGIT+ CD8+ T cells areassociated with pathogenesis and progression of patients with hepatitis Bvirus-related hepatocellular carcinoma. Cancer Immunol Immunother. 2019 Dec;68(12):2041-2054.

23. Kong Y (孔雅娴)#, Tian Y#, Hao Y#, Chong X, Xiao J, YangD, Song C, Han J, Dai G, Zhang F, Zheng H, Zhao H*, Zeng H*. Two types of poorimmunological responder showing distinct responses to long-term HAART. Int J Infect Dis.2019 Sep;86:178-187.

24. Kong Y (孔雅娴), Jia B, Zhao C, Claxton DF, Sharma A,Annageldiyev C, Fotos JS, Zeng H, Paulson RF, Prabhu KS, Zheng H*. Downregulationof CD73 Associates with T cell Exhaustion in AML Patients. Journal of Hematology &Oncology. 2019 Apr 24;12(1):40.

25. Song Y, Wang B, Song R, Hao Y, Wang D, LiY, Jiang Y, Xu L, Ma Y, Zheng H, Kong Y(孔雅娴)*, Zeng H*. T-cell Immunoglobulin and ITIMDomain Contributes to CD8+ T-cell Immunosenescence. Aging Cell.2018,17(2):12716.

26. Zhu L#, Kong Y(孔雅娴)#, Zhang J, Claxton DF, Ehmann WC, RybkaWB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, ZhengH. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 inpatients with acute myeloid leukemia. J Hematol Oncol. 2017 Jun19;10(1):124.

27. Kong Y(孔雅娴), Zhu L, Schell TD, Zhang J, Claxton DF,Ehmann WC, Rybka W, George MR, Zeng H*, Zheng H*. T-cell Immunoglobulin andITIM Domain (TIGIT) Associates with CD8+ T cell Exhaustion and Poor ClinicalOutcome in AML Patients. Clin Cancer Res. 2016 Jun15;22(12):3057-66.

28. Kong Y(孔雅娴) , Li Y, Zhang W, Yuan S, Winkler R,Krohnert U, Han J, Lin T, Zhou Y, Miao P, Wang B, Zhang J, Yu Z, Zhang Y, KosanC, Zeng H. Sepsis-Induced Thymic Atrophy is Associated with Defects in EarlyLymphopoiesis. Stem Cells. 2016;34(12):2902-2915.

29. Kong Y(孔雅娴), Zhang J, Claxton DF, Ehmann WC, RybkaWB, Zhu L, Zeng H, Schell TD, Zheng H*. PD-1(hi)TIM-3(+) T cells associate withand predict leukemia relapse in AML patients post allogeneic stem celltransplantation. Blood Cancer J. 2015 Jul 31;5:e330.

30. ZhangH#, He G#, Kong Y(孔雅娴)#, Chen Y, Wang B,Sun X, Jia B, Xie X, Wang X, Chen D, Wei L, Zhang M, Zeng H*, Chen H*.Tumour-activated liver stromal cells regulate myeloid-derived suppressor cellsaccumulation in the liver. Clin Exp Immunol. 2017Apr;188(1):96-108.

教育经历

1999.09-2004.07 北京大学医学部，临床医学专业，医学学士

2004.09-2009.07 北京大学医学部，干细胞中心，理学博士，细胞生物学，导师李凌松教授

工作经历

2009.08-2014.10  首都医科大学附属北京地坛医院，传染病研究所，助理研究员

2014.12-2015.08  美国宾夕法尼亚州立大学，访问学者

2014.11-2019.04  首都医科大学附属北京地坛医院，传染病研究所；副研究员，副教授

2017.12-2018.12  美国宾夕法尼亚州立大学，访问学者

2019.12-  至今      首都医科大学附属北京地坛医院，研究员

2023.05- 至今      首都医科大学附属北京地坛医院，教授